Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy.

Tully, Karl H; Jütte, Hendrik; Wirtz, Ralph M; Jarczyk, Jonas; Santiago-Walker, Ademi; Zengerling, Friedemann; Breyer, Johannes; Sikic, Danijel; Kriegmair, Maximilian C; von Hardenberg, Jost; Wullich, Bernd; Taubert, Helge; Weyerer, Veronika; Stoehr, Robert; Bolenz, Christian; Burger, Maximilian; Porubsky, Stefan; Hartmann, Arndt; Roghmann, Florian; Erben, Philipp; Eckstein, Markus

Tully, Karl H; Jütte, Hendrik; Wirtz, Ralph M; Jarczyk, Jonas; Santiago-Walker, Ademi; Zengerling, Friedemann; Breyer, Johannes; Sikic, Danijel; Kriegmair, Maximilian C; von Hardenberg, Jost; Wullich, Bernd; Taubert, Helge; Weyerer, Veronika; Stoehr, Robert; Bolenz, Christian; Burger, Maximilian; Porubsky, Stefan; Hartmann, Arndt; Roghmann, Florian; Erben, Philipp; Eckstein, Markus.

Afiliação

Tully KH; Department of Urology, Marien-Hospital Herne, University Hospital Bochum, Ruhr-University, Bochum. Electronic address: karlh.tully@gmail.com.
Jütte H; Department of Pathology, University Hospital Bochum, University of Bochum, Bochum.
Wirtz RM; STRATIFYER Molecular Pathology GmbH, Cologne.
Jarczyk J; Department of Urology, University Hospital Mannheim, Ruprecht-Karls-University Heidelberg, Mannheim.
Santiago-Walker A; Janssen-Cilag GmbH.
Zengerling F; Department of Urology, University Hospital Ulm, University of Ulm, Ulm.
Breyer J; Department of Urology, Caritas Hospital St. Josef, University of Regensburg, Regensburg.
Sikic D; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen.
Kriegmair MC; Department of Urology, University Hospital Mannheim, Ruprecht-Karls-University Heidelberg, Mannheim.
von Hardenberg J; Department of Urology, University Hospital Mannheim, Ruprecht-Karls-University Heidelberg, Mannheim.
Wullich B; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen.
Taubert H; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen.
Weyerer V; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen.
Stoehr R; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen.
Bolenz C; Department of Urology, University Hospital Ulm, University of Ulm, Ulm.
Burger M; Department of Urology, Caritas Hospital St. Josef, University of Regensburg, Regensburg.
Porubsky S; Department of Pathology, University Hospital Mannheim, Ruprecht-Karls-University Heidelberg, Mannheim.
Hartmann A; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen.
Roghmann F; Department of Urology, Marien-Hospital Herne, University Hospital Bochum, Ruhr-University, Bochum.
Erben P; Department of Urology, University Hospital Mannheim, Ruprecht-Karls-University Heidelberg, Mannheim.
Eckstein M; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen.

Urology ; 157: 93-101, 2021 11.

Article em En | MEDLINE | ID: mdl-34153367

Assuntos

Carcinoma de Células de Transição/tratamento farmacológico; Carcinoma de Células de Transição/metabolismo; Receptores de Fatores de Crescimento de Fibroblastos/genética; Receptores de Fatores de Crescimento de Fibroblastos/metabolismo; Neoplasias Urológicas/tratamento farmacológico; Neoplasias Urológicas/metabolismo; Anticorpos Monoclonais Humanizados/uso terapêutico; Antineoplásicos Imunológicos/uso terapêutico; Carcinoma de Células de Transição/genética; Carcinoma de Células de Transição/secundário; Feminino; Expressão Gênica; Fusão Gênica; Humanos; Inibidores de Checkpoint Imunológico/uso terapêutico; Estimativa de Kaplan-Meier; Masculino; Mutação; Nivolumabe/uso terapêutico; Projetos Piloto; Prognóstico; Modelos de Riscos Proporcionais; RNA Mensageiro/metabolismo; Receptor Tipo 1 de Fator de Crescimento de Fibroblastos/genética; Receptor Tipo 1 de Fator de Crescimento de Fibroblastos/metabolismo; Receptor Tipo 2 de Fator de Crescimento de Fibroblastos/genética; Receptor Tipo 2 de Fator de Crescimento de Fibroblastos/metabolismo; Receptor Tipo 3 de Fator de Crescimento de Fibroblastos/genética; Receptor Tipo 3 de Fator de Crescimento de Fibroblastos/metabolismo; Receptor Tipo 4 de Fator de Crescimento de Fibroblastos/genética; Receptor Tipo 4 de Fator de Crescimento de Fibroblastos/metabolismo; Taxa de Sobrevida; Neoplasias Urológicas/genética; Neoplasias Urológicas/patologia

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células de Transição / Neoplasias Urológicas / Receptores de Fatores de Crescimento de Fibroblastos Tipo de estudo: Prognostic_studies Limite: Female / Humans / Male Idioma: En Revista: Urology Ano de publicação: 2021 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google